Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.
US jobs and R&D spending are on the line if US drug pricing reform measures pass paving the way for the government to directly negotiate Medicare drug prices with manufacturers, big pharma leaders warned during an industry-sponsored press briefing on 8 September.
US drug pricing reform measures are looming large in the minds of industry leaders and investors as the Democratic-controlled Congress...
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
EFPIA says reforms make the continent less attractive for innovative firms.
Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.
The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
The Belgian drugmaker is boosting its biologics capacity over the pond.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
